Devyser wins breakthrough contract in Canada for non-invasive fetal RHD testing
Devyser has been awarded a tender from Héma-Québec, in Québec, Canada, for its non-invasive fetal RHD detection product, used to determine fetal RHD status from maternal plasma in early pregnancy. The tender is initially valid over three years starting in 2023, with a potential extension of two additional years. The total possible order value amounts to just over 16 MSEK. “This is a strategic breakthrough in the North American market, and I am very proud of the entire team who made this happen”, says CEO Fredrik Alpsten. “National and regional screening programs represent an important